Key insights
- Citizens reiterates a Market Outperform rating on CRISPR Therapeutics (CRSP) with an $80 price target, citing positive Casgevy data in children that could expand the patient population by 10-15%. While InvestingPro data suggests the stock may be overvalued relative to its fair value, 11 analysts have revised earnings upwards. Recent convertible note issuance strengthens the balance sheet, with other analysts maintaining Buy ratings and raising price targets, indicating positive sentiment around Casgevy's commercial ramp-up and pipeline development.
Investing.com - Citizens reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) shares. The stock currently trades at $50.23, representing significant upside to the analyst’s target. However, InvestingPro data suggests the stock is overvalued relative to its Fair Value estimate, placing it among considerations on the most overvalued stocks list. Notably, 11 analysts have revised their earnings upwards for the upcoming period, according to InvestingPro Tips.
The firm noted that CRISPR Therapeutics’ partner Vertex Pharmaceuticals presented Casgevy data in children ages 5-11 at EHA. The data underpins regulatory filings in this younger age cohort in several countries.
Citizens believes the younger patient population should increase the Casgevy patient population by 10-15%. CRISPR Therapeutics is building toward a pipeline of late-stage assets across large cardiovascular and metabolic indications.
The company expects key early readouts in the second half of 2026, supported by an inflection in Casgevy sales. The pipeline development focuses on in-vivo assets.
Citizens maintains its Market Outperform rating and $80 price target, which is derived from a discounted cash flow analysis.
In other recent news, CRISPR Therapeutics has been the focus of multiple analyst updates and financial developments. The company recently issued $600 million in convertible notes, due in March 2031, with an effective coupon of 1.73%, leading Piper Sandler to raise its price target to $110 while maintaining an Overweight rating. This cash raise has increased CRISPR Therapeutics’ pro forma cash to an estimated $2.56 billion. BofA Securities has adjusted its price target for the company to $83 from $86, maintaining a Buy rating, noting that the commercial ramp-up of Casgevy continues and the balance sheet is strong following the March convertible issuance.
Morgan Stanley initiated coverage on CRISPR Therapeutics with an equalweight rating and a price target of $60, highlighting the near-term valuation already reflecting much of the upside from Casgevy. Meanwhile, Citizens reiterated a Market Outperform rating with an $80 price target, expressing optimism about the company’s gene-editing prospects, particularly in cardiovascular disease. These recent developments underscore the varied perspectives of analysts on CRISPR Therapeutics’ financial and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.